Evidence map›Paper›PMID 30507718›Full record

ReviewCurrent opinion in allergy and clinical immunology2019

Preventing the development of asthma: stopping the allergic march.

Michelle C Maciag, Wanda Phipatanakul

Abstract readReview
In one paragraph

Review in Current opinion in allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Michelle C MaciagDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Wanda Phipatanakul
Boston Children's Hospital · USHarvard University · US

Funding

Controlling and preventing Asthma progression and Severity in Kids (CASK)U01AI126614 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2016 to 2023
$21.0M
MOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1M
SICAS- Diversity SupplementU01AI110397 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2015 to 2020
$8.8M
Environmental Risk Factors for Pediatric Sleep Disordered BreathingR01HL137192 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2017 to 2020
$3.5M
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood AsthmK24AI106822 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2013 to 2022
$1.9M
NHLBI NIH HHS R01 HL137192NIAID NIH HHS K24 AI106822NIAID NIH HHS T32 AI007512NIAID NIH HHS U01 AI110397NIAID NIH HHS U01 AI126614
6 · The paper itself

Abstract

purpose of reviewTo describe important precipitants of asthma and allergic disease, to highlight the links between these triggers and modifications within the immune system, and to examine innovative research regarding asthma prevention with focus on attenuating the atopic march. RECENT

findingsAllergen avoidance, allergen immunotherapy, IgE antagonists, prevention and treatment of respiratory infections, as well as management of gastrointestinal and respiratory dysbiosis have been considered as strategies in asthma prevention. Antenatal vitamin D supplementation in expectant mothers and aggressive control of atopic dermatitis to prevent the development of other allergic conditions were carefully studied as well. SUMMARY: Asthma is a major cause of morbidity and lost productivity. Despite the tremendous burden of this disease, the scientific community is still struggling to find an effective means of prevention. The contribution of genetics to the development of atopy cannot be altered, but environmental changes as well as pharmacotherapy have been studied as modifiable risk factors. Many trials to date have been effective only for subjects with certain characteristics. This is likely because asthma is a heterogenous condition, with a variety of triggers and clinical phenotypes. Thus far, a universally effective prevention strategy has eluded us. However, if an intervention can be found to prevent asthma and the allergic march, it will greatly improve quality of life for millions of sufferers and decrease healthcare expenditures.

Indexed as

Immune SystemAllergensAntibodies, BlockingAsthmaDesensitization, ImmunologicGastrointestinal MicrobiomeHumansHypersensitivityImmunoglobulin EQuality of LifeAllergensAntibodies, BlockingImmunoglobulin E

Identifiers

PMID30507718
PMCPMC6395504
OpenAlexW2903279823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.